Document is current
Any future updates will be listed below
-
Authors
Capel, Henriette L. https://orcid.org/0000-0002-3757-5313
Ellmen, Isaac https://orcid.org/0000-0001-5556-2965
Murray, Chris J.
Mignone, Giulia
Black, Megan
Clarke, Brendan
Breen, Conor
Tierney, Sean
Dougan, Patrick
Buick, Richard J.
Greenshields-Watson, Alexander https://orcid.org/0000-0002-8740-9823
Deane, Charlotte M. https://orcid.org/0000-0003-1388-2252
-
Funding
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/S024093/1)
RCUK | Engineering and Physical Sciences Research Council (EP/S024093/1)
Fusion Antibodies plc
Exscientia
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 6 February 2026
First Online: 21 February 2026
Competing interests
: R.J.B. is a director and shareholder in Fusion Antibodies plc. C.J.M., G.M., M.B., B.C., C.B., S.T., and P.D. were employed by Fusion Antibodies plc. C.M.D. discloses membership of the Scientific Advisory Board of Fusion Antibodies plc and AI proteins, and is a founder of DaltonTx. All other authors declare no conflict of interest.
